PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Login

 

FREE TO ALL REGISTERED HEALTHCARE PROFESSIONALS AND RESEARCHERS WORLDWIDE

Members will receive:

  • Regular e-newsletters with news and analysis of clinical and scientific developments
  • Expert commentaries reviewing clinical trial data on publication
  • Discussions exploring the possible clinical consequences of new data
  • Webinars and other interactive programmes
  • Access to rapidly expanding and regularly updated educational resources including slide presentations
If you are having difficulties logging in, please check your inbox as you may have been sent an email to verify your login.


About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.

LIB Therapeutics

Novartis

Sanofi

© Copyright 2026 PCSK9 Forum. All rights reserved